These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 16496485)

  • 41. Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations.
    Wu DB; Lee EH; Chung WS; Chow DP; Lee VW; Wong MC; Lee KK
    Psychiatry Res; 2013 Dec; 210(3):745-50. PubMed ID: 24012164
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Looking beyond the formulary budget in cost-benefit analysis.
    Cohen LJ
    Am J Manag Care; 1997 Feb; 3 Suppl():S11-7. PubMed ID: 10180337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risks versus benefits of different types of long-acting injectable antipsychotics.
    McEvoy JP
    J Clin Psychiatry; 2006; 67 Suppl 5():15-8. PubMed ID: 16822092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Maintenance pharmacotherapy of schizophrenia: remission and the effectiveness of long-acting risperidone therapy].
    Sárosi A
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):179-87. PubMed ID: 17211053
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China.
    Yang L; Li M; Tao LB; Zhang M; Nicholl MD; Dong P
    Value Health; 2009; 12 Suppl 3():S66-9. PubMed ID: 20586985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-acting injectable risperidone.
    Ehret MJ; Fuller MA
    Ann Pharmacother; 2004 Dec; 38(12):2122-7. PubMed ID: 15522979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.
    Olivares JM; Peuskens J; Pecenak J; Resseler S; Jacobs A; Akhras KS;
    Curr Med Res Opin; 2009 Sep; 25(9):2197-206. PubMed ID: 19604073
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
    Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
    J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.
    Thyssen A; Remmerie B; D'Hoore P; Kushner S; Mannaert E
    Clin Ther; 2007 Feb; 29(2):290-304. PubMed ID: 17472821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
    Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-acting risperidone and oral antipsychotics in unstable schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Fiore L; Valley D; Thwin SS; Vertrees JE; Liang MH;
    N Engl J Med; 2011 Mar; 364(9):842-51. PubMed ID: 21366475
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
    J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone.
    Schmauss M; Sacchetti E; Kahn JP; Medori R
    Int Clin Psychopharmacol; 2007 Mar; 22(2):85-92. PubMed ID: 17293708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland.
    Einarson TR; Pudas H; Zilbershtein R; Jensen R; Vicente C; Piwko C; Hemels ME
    J Med Econ; 2013 Sep; 16(9):1096-105. PubMed ID: 23844621
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacoeconomics of antipsychotic drug therapy.
    Hargreaves WA; Shumway M
    J Clin Psychiatry; 1996; 57 Suppl 9():66-76. PubMed ID: 8823354
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.
    Ereshefsky L; Mascarenas CA
    J Clin Psychiatry; 2003; 64 Suppl 16():18-23. PubMed ID: 14680415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.